For illustrative purposes only.

Welcome to PURPOSE 2

Even though a variety of prevention options exist, HIV remains a serious health concern for many people around the world.

In the United States, socioeconomic inequity, racism, stigma, homophobia, transphobia, and other factors have led to higher rates of HIV in some communities. PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex.

The study was designed to include groups who are underrepresented in HIV prevention trials and are disproportionately affected by the HIV epidemic.

Do you qualify?

More information about the PURPOSE 2 study can also be found at clinicaltrials.gov.

For illustrative purposes only.

"How Is This Related to Me?"

First, this is an opportunity to advance our knowledge of HIV prevention and help develop more PrEP options.

Answer 3 quick questions below to find out if you're eligible to participate in PURPOSE 2.

Second, this is a chance to help change how medical research is done.

Key groups including Black and transgender people have been underrepresented in clinical trials. It's time to change that. We are committed to fair inclusion of all groups in PURPOSE 2, so that what we learn can benefit all.

Find out more about PURPOSE 2 to see if you could be a part of advancing HIV prevention and changing medical research for the better.

Do you qualify?
For illustrative purposes only.

A Global Problem Deserves a Global Effort

PURPOSE 2 is being done in the United States, South Africa, Peru, and Brazil, and will include cisgender men, transgender women, transgender men, and gender non-binary individuals who have sex with partners assigned male at birth.

Do you qualify?

Our Commitment to Inclusion

From day 1, Gilead designed the PURPOSE 2 study with all people who would benefit from PrEP in mind.

Explore a video from Moupali Das, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE 2 add study sites in new locations in the country.

Global Community Advisors

Explore a video from Moupali Das, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE 2 add study sites in new locations in the country.

Global Community Advisors
For illustrative purposes only.

PURPOSE 2 Questionnaire

Thank you for your interest in participating in the PURPOSE 2 study.

Your privacy matters to us. Note that your answers will only be used to let you know whether or not you qualify, and will not be stored or tracked in any way.

*If you are younger than 18 years of age, please contact your local clinical trial site and learn about their requirements.